25.63
-0.96 (-3.61%)
| Penutupan Terdahulu | 26.59 |
| Buka | 26.55 |
| Jumlah Dagangan | 1,231,512 |
| Purata Dagangan (3B) | 2,981,206 |
| Modal Pasaran | 3,195,827,712 |
| Harga / Jualan (P/S) | 81.23 |
| Harga / Buku (P/B) | 8.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -583.86% |
| EPS Cair (TTM) | -11.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.94% |
| Nisbah Semasa (MRQ) | 3.73 |
| Aliran Tunai Operasi (OCF TTM) | -291.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -169.99 M |
| Pulangan Atas Aset (ROA TTM) | -101.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -247.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alumis Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 53.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 30 Sep 2025 | 15,139,706 |
| Foresite Capital Management V, Llc | 30 Sep 2025 | 5,779,348 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 46.00 (Raymond James, 79.48%) | Beli |
| Median | 38.00 (48.26%) | |
| Rendah | 32.00 (Guggenheim, 24.85%) | Beli |
| 32.00 (Leerink Partners, 24.85%) | Beli | |
| Purata | 37.88 (47.80%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 21.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Raymond James | 11 Mar 2026 | 46.00 (79.48%) | Beli | 26.34 |
| Stifel | 25 Feb 2026 | 44.00 (71.67%) | Beli | 29.39 |
| Chardan Capital | 21 Jan 2026 | 37.00 (44.36%) | Beli | 26.68 |
| HC Wainwright & Co. | 09 Jan 2026 | 40.00 (56.07%) | Beli | 19.56 |
| Guggenheim | 07 Jan 2026 | 32.00 (24.85%) | Beli | 17.92 |
| Leerink Partners | 07 Jan 2026 | 32.00 (24.85%) | Beli | 17.92 |
| Morgan Stanley | 07 Jan 2026 | 33.00 (28.76%) | Beli | 17.92 |
| Wells Fargo | 06 Jan 2026 | 39.00 (52.17%) | Beli | 16.23 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Alumis to Participate in Upcoming February Investor Conferences |
| 09 Jan 2026 | Pengumuman | Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 07 Jan 2026 | Pengumuman | Alumis Announces Pricing of Upsized Public Offering of Common Stock |
| 06 Jan 2026 | Pengumuman | Alumis Announces Proposed Public Offering of Common Stock |
| 06 Jan 2026 | Pengumuman | Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program |
| 05 Jan 2026 | Pengumuman | Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |